- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02043600
Randomized-controlled Trial of Yoga for Ulcerative Colitis
September 22, 2015 updated by: Holger Cramer, Universität Duisburg-Essen
The aim of this randomized trial is to investigate the effects of a 12-week yoga intervention compared to self-care on quality of life, stress, psychological health, and physiological parameters in 77 patients with ulcerative colitis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
77
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Essen, Germany, 45276
- Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ulcerative colitis (clinical, endoscopic and histological diagnosis)
- Disease duration at least 12 months
- Clinical remission for at least 4 weeks and less than 12 months
- CAI < 5
- IBDQ < 170
- Physical and mental ability to perform yoga
- No regular practice of yoga or Pilates in the previous 12 months
Exclusion Criteria:
- Clinically active disease (CAI > 4 Rachmilewitz)
- Complete resection of the colon
- Acute, infectious or chronic active ulcerative colitis
- Severe disease precluding yoga practice
- Malignancy with a disease-free survival < 5 years except curatively treated basalioma of the skin
- Alcohol or drug abuse
- Dementia
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Yoga
|
12-week Hatha Yoga intervention 90 minutes once a week
|
|
ACTIVE_COMPARATOR: Self-care
|
Self-care books are provided for self-directed use
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease-specific quality of life
Time Frame: 3 months
|
Inflammatory Bowel Disease Questionnaire (IBDQ)
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease-specific quality of life
Time Frame: 6 months
|
Inflammatory Bowel Disease Questionnaire (IBDQ)
|
6 months
|
|
Generic quality of life
Time Frame: 3 months
|
36-Item Short Form Health Survey (SF-36)
|
3 months
|
|
Generic quality of life
Time Frame: 6 months
|
36-Item Short Form Health Survey (SF-36)
|
6 months
|
|
Anxiety/depression
Time Frame: 3 months
|
Hospital Anxiety and Depresion Scale (HADS)
|
3 months
|
|
Anxiety/depression
Time Frame: 6 months
|
Hospital Anxiety and Depresion Scale (HADS)
|
6 months
|
|
Subjective stress
Time Frame: 3 months
|
Perceived Stress Scale (PSS)
|
3 months
|
|
Subjective stress
Time Frame: 6 months
|
Perceived Stress Scale (PSS)
|
6 months
|
|
Subjective stress
Time Frame: 3 months
|
Perceived Stress Questionnaire (PSQ)
|
3 months
|
|
Subjective stress
Time Frame: 6 months
|
Perceived Stress Questionnaire (PSQ)
|
6 months
|
|
Positive/negative affect
Time Frame: 3 months
|
Positive and Negative Affect Schedule (PANAS)
|
3 months
|
|
Positive/negative affect
Time Frame: 6 months
|
Positive and Negative Affect Schedule (PANAS)
|
6 months
|
|
Body awareness
Time Frame: 3 months
|
Body Awareness Questionnaire (BAQ)
|
3 months
|
|
Body awareness
Time Frame: 6 months
|
Body Awareness Questionnaire (BAQ)
|
6 months
|
|
Body responsiveness
Time Frame: 3 months
|
Body Responsiveness Scale (BRS)
|
3 months
|
|
Body responsiveness
Time Frame: 6 months
|
Body Responsiveness Scale (BRS)
|
6 months
|
|
Self-efficacy
Time Frame: 3 months
|
General Self-Efficacy Scale
|
3 months
|
|
Self-efficacy
Time Frame: 6 months
|
General Self-Efficacy Scale
|
6 months
|
|
C-reactive protein
Time Frame: 3 months
|
C-reactive protein
|
3 months
|
|
C-reactive protein
Time Frame: 6 months
|
C-reactive protein
|
6 months
|
|
Blood sedimentation rate
Time Frame: 3 months
|
Blood sedimentation rate
|
3 months
|
|
Blood sedimentation rate
Time Frame: 6 months
|
Blood sedimentation rate
|
6 months
|
|
Faecal calprotectin
Time Frame: 3 months
|
Faecal calprotectin
|
3 months
|
|
Faecal calprotectin
Time Frame: 6 months
|
Faecal calprotectin
|
6 months
|
|
Faecal lactoferrin
Time Frame: 3 months
|
Faecal lactoferrin
|
3 months
|
|
Faecal lactoferrin
Time Frame: 6 months
|
Faecal lactoferrin
|
6 months
|
|
Faecel PMN-elastase
Time Frame: 3 months
|
Faecel PMN-elastase
|
3 months
|
|
Faecel PMN-elastase
Time Frame: 6 months
|
Faecel PMN-elastase
|
6 months
|
|
Disease activity
Time Frame: 3 months
|
Clinical Activity Index (CAI-Rachmilewitz)
|
3 months
|
|
Disease activity
Time Frame: 6 months
|
Clinical Activity Index (CAI-Rachmilewitz)
|
6 months
|
|
Salivary cortisol level
Time Frame: 3 months
|
Salivary cortisol level - cortisol awakening response
|
3 months
|
|
Steroid sensitivity
Time Frame: 3 months
|
Steroid sensitivity (IC50)
|
3 months
|
|
Andrenergic sensitivity
Time Frame: 3 months
|
Andrenergic sensitivity (IC50)
|
3 months
|
|
Cholinergic sensitivity
Time Frame: 3 months
|
Cholinergic sensitivity (IC50)
|
3 months
|
|
Safety
Time Frame: 3 months
|
Number of patients with adverse events/serious adverse events
|
3 months
|
|
Safety
Time Frame: 6 months
|
Number of patients with adverse events/serious adverse events
|
6 months
|
|
Hemogram
Time Frame: 3 months
|
Hemogram
|
3 months
|
|
Hemogram
Time Frame: 6 months
|
Hemogram
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence
Time Frame: 3 months
|
Intervention adherence (number of sessions attended and home practice diary)
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Holger Cramer, PhD, Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
- Study Director: Jost Langhorst, MD, Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Koch AK, Schols M, Langhorst J, Dobos G, Cramer H. Perceived stress mediates the effect of yoga on quality of life and disease activity in ulcerative colitis. Secondary analysis of a randomized controlled trial. J Psychosom Res. 2020 Mar;130:109917. doi: 10.1016/j.jpsychores.2019.109917. Epub 2019 Dec 31.
- Cramer H, Schafer M, Schols M, Kocke J, Elsenbruch S, Lauche R, Engler H, Dobos G, Langhorst J. Randomised clinical trial: yoga vs written self-care advice for ulcerative colitis. Aliment Pharmacol Ther. 2017 Jun;45(11):1379-1389. doi: 10.1111/apt.14062. Epub 2017 Apr 5.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (ACTUAL)
May 1, 2015
Study Completion (ACTUAL)
August 1, 2015
Study Registration Dates
First Submitted
January 21, 2014
First Submitted That Met QC Criteria
January 21, 2014
First Posted (ESTIMATE)
January 23, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
September 23, 2015
Last Update Submitted That Met QC Criteria
September 22, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-5560-BO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colitis, Ulcerative
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Eli Lilly and CompanyRecruitingUlcerative Colitis, Active Severe | Ulcerative Colitis (UC) | Ulcerative Colitis, Active ModerateUnited States, China, Croatia, France, India, Japan, Israel, Taiwan, Brazil, Serbia, Greece, Hungary, Argentina, Italy, Poland, Czechia, Colombia, Lithuania, Latvia, Ukraine, South Africa, Portugal, Mexico, Canada, Slovakia, Turkey (Türkiye) and more
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtCompletedUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Alexion Pharmaceuticals, Inc.Immune PharmaceuticalsTerminatedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael
-
Odyssey TherapeuticsRecruitingUlcerative Colitis (UC) | UC - Ulcerative ColitisAustralia, Austria, Jordan, Poland, Ukraine, New Zealand, Canada, Czechia, Lithuania, Moldova
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; MRSU 938 - Research Center of Saint...Not yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncActive, not recruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Tanta UniversityRecruitingUlcerative Colitis | Ulcerative Colitis (UC)Egypt
Clinical Trials on Yoga
-
Universität Duisburg-EssenCompleted
-
Ataturk UniversityKTO Karatay UniversityRecruiting
-
Adiyaman University Research HospitalCompletedDepression | Stress | Anxiety | Psychological ResilienceTurkey
-
NMP Medical Research InstituteYog-Kulam; Department of Zoology, University of Rajasthan, IndiaCompleted
-
NMP Medical Research InstituteWarwick Research Services; Yog-KulamCompleted
-
Northwestern UniversityCompleted
-
University of MinnesotaCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedDepression | Pain | Breast Cancer | FatigueUnited States
-
Saglik Bilimleri UniversitesiThe Scientific and Technological Research Council of TurkeyCompletedStress | Anxiety | Telerehabilitation | Yoga | University StudentsTurkey
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedProstate CarcinomaUnited States